Valeur202020212022202320242025TTMFrais de vente, généraux et administratifs9.8 M10.86 M10.32 M9.73 M9.44 M8.89 M—Recherche et développement22.76 M28.69 M30.65 M34.47 M24.81 M22.76 M—Résultat d'exploitation-31.5 M-35.07 M-35.37 M-12.99 M-14.89 M31.33 M—Total des produits hors exploitation1.83 M893 K1.78 M3.25 M5.22 M4.1 M—Charges d'intérêts, nettes des intérêts capitalisés———————Résultat hors exploitation, hors charges d'intérêts1.83 M893 K1.78 M3.25 M5.22 M4.1 M—Revenus/dépenses exceptionnels———————Résultat avant impôts-29.7 M-34.2 M-33.64 M-9.78 M-9.71 M35.4 M-17.73 MPart des actionnaires dans le résultat———————Impôts0058 K8.97 M4.52 M54 K—Intérêts ne donnant pas le contrôle / intérêts minoritaires———————Autres produits/charges après impôts———————Résultat net avant activités abandonnées-29.7 M-34.2 M-33.69 M-18.75 M-14.23 M35.34 M-17.94 MActivités abandonnées———————Résultat net-29.7 M-34.2 M-33.69 M-18.75 M-14.23 M35.34 M-17.94 MAjustement de dilution———————Dividendes privilégiés———————Résultat net dilué revenant aux actionnaires ordinaires-29.7 M-34.2 M-33.69 M-18.75 M-14.23 M35.34 M-17.94 MBénéfice par action de base (BPA de base)-0.37-0.41-0.39-0.21-0.160.38—Bénéfice par action dilué (BPA dilué)-0.37-0.41-0.39-0.21-0.160.38-0.23Nombre moyen d'actions de base en circulation79.59 M84.2 M86.56 M87.63 M89.53 M93.43 M—Nombre d'actions en circulation après dilution79.59 M84.2 M86.56 M87.63 M89.53 M93.82 M—EBITDA-29.95 M-33.32 M-28.87 M-12.19 M-14.4 M31.8 M—EBIT-31.5 M-35.07 M-35.37 M-12.99 M-14.89 M31.33 M—Coût des ventes60 K680 K975 K2 M7.93 M9.25 M—Autres coûts des ventes———————Amortissements (flux de trésorerie)1.54 M1.75 M6.5 M801 K486 K475 K—
Compugen Ltd. - Ordinary Shares
Compugen Ltd. is a clinical-stage publicly traded predictive drug discovery and development company headquartered in Israel, with shares traded on the NASDAQ Capital Market and on the Tel Aviv Stock Exchange. Compugen was established as computational drug discovery service provider in 1993. Compugen originally acted as service provider for pharma companies, supplying its software and computational services to predict different types of biological phenomena. It had arrangements with big companies such as Novartis AG, Abbot Laboratories and Pfizer Inc. Subsequently, Compugen made a decision to become a drug development company with its own internal pipeline, and in 2010, decided to a focus on oncology and immunology. OncoMed Pharmaceuticals and Five Prime Therapeutics are among Compugen's competitors.